AXON, with NO drugs in the pipeline but touted hea
Post# of 72439
I call BS. If anyone feels like fighting the creeps elsewhere with some facts, try this:
AXON market cap (zero drugs in pipeline) 254.196 million (down from 3 Billion)
IPIX market cap (3 drugs with multiple successful clinical trials) 101.592 million
Quote:
During Axovant’s very brief JPM session, a subdued David Hung gave a postmortem of intepirdine’s failure in clear-cut, although rather monotone, terms. He said next steps include “working with Roivant to expand our pipeline and find attractive candidates, while also conducting a portfolio review over our assets, and prioritizing our candidates.” He said he would provide an update of that review to the Street by the end of the quarter.